Reviewing Subsidies for Targeted Eczema Therapies and Providing Considerations for Patient Eligibility, Subsidy Duration and Cost Effectiveness
- MOH will review subsidies for targeted eczema therapies like biologics and JAK inhibitors.
- Some immunosuppressants and abrocitinib are already subsidised for eligible patients.
- Subsidies hinge on clinical and cost-effectiveness, factoring price, efficacy, and alternatives.